IMPORTANCE: Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States. OBJECTIVE: To determine the frequency of the APP A673T variant in a large group of elderly cognitively normal controls and AD cases from the United States and in 2 case-control cohorts from Sweden. DESIGN, SETTING, AND PARTICIPANTS: Case-control association analysis of variant APP A673T in US and Swedish white individuals comparing AD cases with cognitively intact elderly controls. Participants were ascertained at multiple university-associated medical centers and clinics across the United States and Sweden by study-specific sampling methods. They were from case-control studies, community-based prospective cohort studies, and studies that ascertained multiplex families from multiple sources. MAIN OUTCOMES AND MEASURES: Genotypes for the APP A673T variant were determined using the Infinium HumanExome V1 Beadchip (Illumina, Inc) and by TaqMan genotyping (Life Technologies). RESULTS: The A673T variant genotypes were evaluated in 8943 US AD cases, 10 480 US cognitively normal controls, 862 Swedish AD cases, and 707 Swedish cognitively normal controls. We identified 3 US individuals heterozygous for A673T, including 1 AD case (age at onset, 89 years) and 2 controls (age at last examination, 82 and 77 years). The remaining US samples were homozygous for the alanine (A673) allele. In the Swedish samples, 3 controls were heterozygous for A673T and all AD cases were homozygous for the A673 allele. We also genotyped a US family previously reported to harbor the A673T variant and found a mother-daughter pair, both cognitively normal at ages 72 and 84 years, respectively, who were both heterozygous for A673T; however, all individuals with AD in the family were homozygous for A673. CONCLUSIONS AND RELEVANCE: The A673T variant is extremely rare in US cohorts and does not play a substantial role in risk for AD in this population. This variant may be primarily restricted to Icelandic and Scandinavian populations.
IMPORTANCE: Recently, a rare variant in the amyloid precursor protein gene (APP) was described in a population from Iceland. This variant, in which alanine is replaced by threonine at position 673 (A673T), appears to protect against late-onset Alzheimer disease (AD). We evaluated the frequency of this variant in AD cases and cognitively normal controls to determine whether this variant will significantly contribute to risk assessment in individuals in the United States. OBJECTIVE: To determine the frequency of the APP A673T variant in a large group of elderly cognitively normal controls and AD cases from the United States and in 2 case-control cohorts from Sweden. DESIGN, SETTING, AND PARTICIPANTS: Case-control association analysis of variant APP A673T in US and Swedish white individuals comparing AD cases with cognitively intact elderly controls. Participants were ascertained at multiple university-associated medical centers and clinics across the United States and Sweden by study-specific sampling methods. They were from case-control studies, community-based prospective cohort studies, and studies that ascertained multiplex families from multiple sources. MAIN OUTCOMES AND MEASURES: Genotypes for the APP A673T variant were determined using the Infinium HumanExome V1 Beadchip (Illumina, Inc) and by TaqMan genotyping (Life Technologies). RESULTS: The A673T variant genotypes were evaluated in 8943 US AD cases, 10 480 US cognitively normal controls, 862 Swedish AD cases, and 707 Swedish cognitively normal controls. We identified 3 US individuals heterozygous for A673T, including 1 AD case (age at onset, 89 years) and 2 controls (age at last examination, 82 and 77 years). The remaining US samples were homozygous for the alanine (A673) allele. In the Swedish samples, 3 controls were heterozygous for A673T and all AD cases were homozygous for the A673 allele. We also genotyped a US family previously reported to harbor the A673T variant and found a mother-daughter pair, both cognitively normal at ages 72 and 84 years, respectively, who were both heterozygous for A673T; however, all individuals with AD in the family were homozygous for A673. CONCLUSIONS AND RELEVANCE: The A673T variant is extremely rare in US cohorts and does not play a substantial role in risk for AD in this population. This variant may be primarily restricted to Icelandic and Scandinavian populations.
Authors: Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson Journal: Nature Date: 2012-08-02 Impact factor: 49.962
Authors: E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance Journal: Science Date: 1993-08-13 Impact factor: 47.728
Authors: W A Kukull; G D Schellenberg; J D Bowen; W C McCormick; C E Yu; L Teri; J D Thompson; E S O'Meara; E B Larson Journal: J Clin Epidemiol Date: 1996-10 Impact factor: 6.437
Authors: E H Corder; A M Saunders; N J Risch; W J Strittmatter; D E Schmechel; P C Gaskell; J B Rimmler; P A Locke; P M Conneally; K E Schmader Journal: Nat Genet Date: 1994-06 Impact factor: 38.330
Authors: E Levy-Lahad; W Wasco; P Poorkaj; D M Romano; J Oshima; W H Pettingell; C E Yu; P D Jondro; S D Schmidt; K Wang Journal: Science Date: 1995-08-18 Impact factor: 47.728
Authors: E Levy-Lahad; E M Wijsman; E Nemens; L Anderson; K A Goddard; J L Weber; T D Bird; G D Schellenberg Journal: Science Date: 1995-08-18 Impact factor: 47.728
Authors: Xiaoling Zhang; Congcong Zhu; Gary Beecham; Badri N Vardarajan; Yiyi Ma; Daniel Lancour; John J Farrell; Jaeyoon Chung; Richard Mayeux; Jonathan L Haines; Gerard D Schellenberg; Margaret A Pericak-Vance; Kathryn L Lunetta; Lindsay A Farrer Journal: Alzheimers Dement Date: 2019-01-03 Impact factor: 21.566
Authors: Chia-Chen Liu; Melissa E Murray; Xia Li; Na Zhao; Na Wang; Michael G Heckman; Francis Shue; Yuka Martens; Yonghe Li; Ana-Caroline Raulin; Cassandra L Rosenberg; Sydney V Doss; Jing Zhao; Melissa C Wren; Lin Jia; Yingxue Ren; Tadafumi C Ikezu; Wenyan Lu; Yuan Fu; Thomas Caulfield; Zachary A Trottier; Joshua Knight; Yixing Chen; Cynthia Linares; Xue Wang; Aishe Kurti; Yan W Asmann; Zbigniew K Wszolek; Glenn E Smith; Prashanthi Vemuri; Kejal Kantarci; David S Knopman; Val J Lowe; Clifford R Jack; Joseph E Parisi; Tanis J Ferman; Bradley F Boeve; Neill R Graff-Radford; Ronald C Petersen; Steven G Younkin; John D Fryer; Hu Wang; Xianlin Han; Carl Frieden; Dennis W Dickson; Owen A Ross; Guojun Bu Journal: Sci Transl Med Date: 2021-09-29 Impact factor: 19.319